APA-viite

Campbell, D., Blazer, M., Bloudek, L., Brokars, J., & Makenbaeva, D. (2019). Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia. Am Health Drug Benefits.

Chicago-tyylinen lähdeviittaus

Campbell, David, Marlo Blazer, Lisa Bloudek, John Brokars, ja Dinara Makenbaeva. "Realized and Projected Cost-Savings From the Introduction of Generic Imatinib Through Formulary Management in Patients With Chronic Myelogenous Leukemia." Am Health Drug Benefits 2019.

MLA-viite

Campbell, David, et al. "Realized and Projected Cost-Savings From the Introduction of Generic Imatinib Through Formulary Management in Patients With Chronic Myelogenous Leukemia." Am Health Drug Benefits 2019.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.